Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial
Author:
Affiliation:
1. Pfizer Inc. La Jolla California USA
2. The University of Texas MD Anderson Cancer Center Houston Texas USA
3. Pfizer Inc. San Francisco California USA
4. Pfizer Inc. Cambridge Massachusetts USA
5. Pfizer Inc. Collegeville Pennsylvania USA
Funder
Pfizer
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1623
Reference15 articles.
1. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
2. PARP inhibitors: Synthetic lethality in the clinic
3. PfizerInc.TALZENNA™ (talazoparib) [prescribing information].http://labeling.pfizer.com/ShowLabeling.aspx?id=11046. Accessed November 8 2019.
4. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
5. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method;Heliyon;2023-11
2. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments;European Journal of Cancer;2023-09
3. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology;Clinical Pharmacokinetics;2023-08-16
4. Effects of MAPK pathway inhibitors (AZD6244) on resistance of breast cancer cells to chemotherapy and targeted therapy;Materials Express;2023-01-01
5. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology;Clinical Pharmacokinetics;2022-10-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3